# Apnar Pharma LLP – FDA Inspection, May 22, 2026

Source: https://www.keypedia.com/records/fda_inspections/apnar-pharma-llp/2e3ecc9e-96a0-4a56-a416-b610ed28e8c8
Source feed: FDA_Inspections

> FDA inspection 1301816 of Apnar Pharma LLP, May 22, 2026. 2 citations under 21 CFR part 211. Form 483 issued. 2 other FDA inspections on record for this company.

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1301816
- Company Name: Apnar Pharma LLP
- Inspection Date: 2026-05-22
- Project Area: Drug Quality Assurance
- Product Type: Human Drugs
- Center: Human Drugs
- Office Name: New Jersey District Office
- Citation Count: 2

## Related Documents

- FDA Inspection 1182133 - 2022-09-01
- [FDA Inspection 932607 - 2015-07-10](https://www.keypedia.com/records/fda_inspections/apnar-pharma-llp/19815bfe-8bf5-406d-903c-55ffc5fbda97)

## Related Officers

- [Ankur C. Patel](https://www.keypedia.com/people/ankur-c-patel/602c7d14-2c48-4929-a07b-6e4c235d7f13)

Company: https://www.keypedia.com/companies/apnar-pharma-llp/97e27879-d20b-4281-b876-7dbab65dc29d

Office: https://www.keypedia.com/offices/new-jersey-district-office/6ff5e2e9-5cff-44c7-af24-5a55329a8248